Approved accessible "mitapivat tablets"

PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase. PYRUKYND is a prescription medicine used to treat low red blood cell counts caused by the early breakdown of red blood cells (hemolytic anemia) in adults with pyruvate kinase deficiency (PK Deficiency). It is not known if PYRUKYND is safe and effective in children.  Active ingredient: mitapivat Inactive ingredients: croscarmellose sodium, mannitol, microcrystalline cellulose, and sodium stearyl fumarate. The tablet film coating contains: FD&C Blue No. 2, hypromellose, lactose monohydrate, titanium dioxide, and triacetin.

Mitapivat is indicated for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency. Mitapivat, sold under the brand name Pyrukynd, is a medication used to treat hemolytic anemia. It is taken as the sulfate hydrate salt by mouth. Mitapivat is a pyruvate kinase activator. Mitapivat was approved for medical use in the United States in February 2022, and in the European Union in November 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

How can 1 go about obtaining mitapivat tablets?

If mitapivat tablets are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).

PYRUKYND (mitapivat) tablets for oral use Initial U.S. Approval: 2022